Group

Topical Treatment

0 day

4th day

8th day

12th day

16th day

20th day

24th day

I

SB

(Negative Control)

315.6 ± 3.3

314.0 ± 1.6

(0.5 ± 0.9)

295.2 ± 3.6

(6.4 ± 1.6)

271.2 ± 2.2

(14.0 ± 0.5)

218.4 ± 3.7

(30.8 ± 0.5)

216.3 ± 3.3

(31.5 ± 1.0)

216.0 ± 2.0

(31.5 ± 0.7)

II

SS

(Positive Control)

342.6 ± 3.6

245.2 ± 2.5*

(28.4 ± 1.3)^a

136.9 ± 3.8*

(60.0 ± 1.8)^a

65.6 ± 3.2*

(80.8 ± 0.8)^a

52.7 ± 2.8*

(84.6 ± 0.9)^a

16.7 ± 2.78

(95.1 ± 0.7)^a

7.7 ± 3.5*

(97.8 ± 1.0)^a

III

LBE

254.5 ± 5.9

206.8 ± 5.9*^#

(18.7 ± 3.6)^ab

158,4 ± 3.1*^#

(37.7 ± 1.0)^ab

157.7 ± 3.6*^#

(38.0 ± 0.6)^ab

108.7 ± 3.0*^#

(57.3 ± 0.2)^ab

56.3 ± 4.1*^#

(77.9 ± 1.1)^ab

27.5 ± 6.9*^#

(89.1 ± 2.9)^ab

IV

LSO-5

336.7 ± 4.2

298.4 ± 3.4*^#¥

(11.4 ± 0.4)^abc

109.0 ± 4.4*^#¥

(67.6 ± 1.5)^abc

13.0 ± 4.3*^#¥

(96.2 ± 1.2)^abc

10.6 ± 2.6*^#¥

(96.8 ± 0.7)^abc

4.8 ± 3.1*^#¥

(98.6 ± 0.9)^abc

0.5 ± 0.9*^¥

(99.9 ± 0.3)^ac

V

LSO-10

257.8 ± 4.9

223.9 ± 4.8*^#¥

(13.1 ± 2.7)^abc

102.9 ± 1.6*^#¥

(60.1 ± .6)^ac

20.0 ± 4.0*^#¥

(92.2 ± 1.4)^abc

17.2 ± 3.1*^#¥

(93.3 ± 1.1)^abc

10.8 ± 2.6*^¥

(95.8 ± 1.0)^ac

4.6 ± 3.4*^¥

(98.2 + 1.3)^ac